Severe asthma treatment: need for characterising patients
- 1 March 2005
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 365 (9463) , 974-976
- https://doi.org/10.1016/s0140-6736(05)71087-4
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy, 2004
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical and Experimental Allergy, 2004
- Published by European Respiratory Society (ERS) ,2003
- Predictors of therapy resistant asthma: outcome of a systematic evaluation protocolThorax, 2003
- Case-control study of severe life threatening asthma (SLTA) in adults: psychological factorsThorax, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional surveyBMJ, 2001
- Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic reviewThorax, 2001
- Brittle asthmaThorax, 1998